The objective of this study is to investigate the proportion of HER2 overexpression in gastric cancer patients group, to evaluate the relation of HER2 overexpression with prognosis, and to analyze the proportion of herceptin applied to patients in clinical field. Furthermore, the investigators are going to reevaluate the clinical benefit of Herceptin for survival prolongation compared to chemotherapy only.
Study Type
OBSERVATIONAL
Enrollment
860
Gangnam Severance Hospital
Seoul, South Korea
The proportion of HER2 overexpression in gastric cancer patients
Time frame: 8 years
Gastric cancer specific survival according to HER2 expression in each stage
Time frame: 5 years
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.